Abbott Laboratories (VIE:ABT)
Austria · Delayed Price · Currency is EUR | Market Cap | 167.70B -14.6% |
| Revenue (ttm) | 40.78B +8.1% |
| Net Income | 4.73B -61.2% |
| EPS | 2.71 -61.2% |
| Shares Out | n/a |
| PE Ratio | 35.47 |
| Forward PE | 19.24 |
| Dividend | 2.13 (2.22%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | n/a |
| Open | 97.76 |
| Previous Close | 98.72 |
| Day's Range | 96.14 - 97.76 |
| 52-Week Range | 70.10 - 116.14 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 14, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott’s Amulet 360 device granted CE Mark
Abbott (ABT) has received CE Mark for the Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation not caused…
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updat...
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' glucose monitor, making it the first device that continuously monitors both ketone levels and blood sugar.
Abbott receives FDA authorization for Libre Duo 10 Day system
Abbott (ABT) announced U.S. Food and Drug Administration authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology. The new biowearable is designed to aler...
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for...
Abbott agrees to $670 million settlement of infant formula cases
Abbott said on Thursday it reached a $670 million settlement with three law firms to resolve legal claims by 2,000 people who alleged harms relating to the company's specialty formulas for preterm i...
Abbott resolves portion of litigation regarding specialty infant formulas
Abbott (ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company’s specialty formulas for preterm in...
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical ...
HealthTab enters collaboration agreement with Abbott
Avricore Health is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement with Abbott (ABT) to supply and distribute Abbott’s point-of-c...
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
The NACHC and Abbott Food for Health Initiative is a multi-year "food is medicine" effort to support the integration of nutrition as a foundational component of primary care provided by Community Heal...
MiniMed announces Flex system shipping in the U.S. with Instinct sensor
MiniMed (MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott (ABT). For the first time, people with diabetes…
Abbott upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Abbott (ABT) to Outperform from Peer Perform with a $130 price target
Wolfe upgrades Abbott to Outperform on 2027 growth pickup
Wolfe Research upgraded Abbott (ABT) to Outperform from Peer Perform with a $130 price target The firm sees the company’s organic growth ramping in 2027. Consensus estimates already reflect “lots…
Abbott price target raised to $125 from $112 at Citi
Citi raised the firm’s price target on Abbott (ABT) to $125 from $112 and keeps a Buy rating on the shares. The firm is more optimistic on the medical technology…
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its hist...
Abbott and Google launch partnership for glucose insights and AI coaching
Abbott (ABT) announced a first-of-its-kind partnership with Google (GOOG) Health to redefine how people understand and manage their health. By combining glucose insights from Abbott’s Lingo biowearabl...
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a...
3 ‘Strong Buy’ Dividend Aristocrat Stocks to Power Your Cash Flow, 7/30/26
Investors searching for regular cash payments can look to Abbott Laboratories ($ABT), CH Robinson ($CHRW), and Linde ($LIN). Top analysts covering these stocks currently rate these dividend aristocrat...
Abbott price target lowered to $125 from $135 at UBS
UBS analyst Patrick Wood lowered the firm’s price target on Abbott (ABT) to $125 from $135 and keeps a Buy rating on the shares after assuming coverage of the name.
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader acces...
Abbott defeats shareholder lawsuit over 2022 infant formula recall
A federal judge on Friday dismissed a lawsuit accusing Abbott Laboratories of defrauding shareholders by downplaying and trying to evade its responsibility for a 2022 recall of powdered infant formu...
Abbott investigates two separate cyber incidents, says no operations affected
Abbott Laboratories is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and its LabCentral portal, the company said on Frid...
Abbott Laboratories Earnings Call Transcript: Q2 2026
Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, with strong momentum in nutrition, diagnostics, and medical devices. Key product launches and pipeline investments support future growth.
Abbott Laboratories Earnings release: Q2 2026
Abbott Laboratories released its Q2 2026 earnings on July 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q2 2026
Abbott Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.